medigraphic.com
A partir del año 2010, la Revista Oficial del INER cambió a NCT (Neumología y Cirugía de Tórax)

 Ver actualización

2003, Number 4

Rev Inst Nal Enf Resp Mex 2003; 16 (4)

Efficacy and Tolerability Comparison of the Salbuterol-Ambroxol Combination or of Salbuterol in the Treatment of Bronchial Asthma in Pediatric Patients: Prospective, Double-Blind, Aleatory and Parallel Study.

Cortés BP, Maza GD, Velásquez SJR, Regalado PJ

Language: Spanish
References: 15
Page: 226-233
PDF size: 134.57 Kb.


ABSTRACT

Introduction: The rise of the asthma at world level, particularly with symptoms in the pediatric age stimulates the study of associations of medications that can be complementary given the physiopathology of the illness. Material and methods: It was carried out a clinical study with the purpose of evaluating the security, tolerability and effectiveness of the combination albuterol-ambroxol, in patient in pediatric age of 6 to 14 years with a crisis of bronchial asthma classified as mild to moderate, with base in respiratory functional tests. The selected patients were assigned from an aleatory way to receive the combination albuterol-ambroxol or only albuterol during a period of 5 days and they were evaluated in the days 1, 3 and 5, through clinical study with base in a scale system and respiratory functional tests. Objective: To know if in this type of patient with exacerbation of their symptoms, some differences exist in relation to the clinical and functional response with the albuterol, medication of well-known efficacy in this pathology and the combination albuterol-ambroxol, agent used in many countries in the world due to its mucolytic effect. Results: A clinical evolution was observed with tendency to the improvement in those patient whom received the combination, the functional response was analyzed to the treatment of each group, being compared with the final measurement of FVC, FEV1 and FEF25-75% and it was found that the combination associated with an improvement statistically significant in the FEF25-75%: (p=0.01). When comparing the spirometric parameters between the first and the last day of the medication it was observed that the group that used the albuterol-ambroxol combination showed an increment respectively in the FVC and the FEF25-75% of the order of 16.8% and 20.6% in comparison with the group that only received albuterol whose increment in the mentioned parameters was of 1% (p< 0.05). Conclusions: This study suggests that the employment of the combination can improve the flow of air at level of peripheric airways in pediatric patient with mild to moderate exacerbations of asthma.


REFERENCES

  1. Global Strategy for Asthma Management and Prevention. National Institutes of Health. National Heart, Lung, and Blood Institute. Revised, 2002.

  2. Sakula A. Charcot-Leyden Crystals and Curshman Spirals in Asthmatic Sputum. Thorax 1986;41:503-507.

  3. Leff AR. Pulmonary and Critical Care Pharmacology and Therapeutics. New York: McGraw-Hill, 1996:681-694.

  4. Serafin WE. Drugs Used in Asthma. In: Hardman J, Molinoff P, Goodman A, editors. The Pharmacological Basis of Therapeutics. 9th ed. New York:McGraw-Hill, 1996:659-682.

  5. Hoggg JC. Pathology of Asthma. In: Holgate ST, editor. Asthma: Physiology, Immunopharmacology and Treatment. London: Academic Press, 1993:17-25.

  6. Curti PC, Genghini M. Role of Surfactant in Alveolar Defense Against Inhaled Particles. Respiration 1989;55 suppl(1):60-67.

  7. Tamaoki J, Chiyotani A, Yamauchi F, Takeuchi S, Takizawa T. Ambroxol Inhibits Na+ Absorption by Canine Airway Epithelial Cells in Culture. J Pharm Pharmacol 1991;43:841-843.

  8. Mistretta A, Crimi N, Palermo F, Oliveri R, Vancheri C, Vigneri G, et al. Lung Permeability in Smokers after Ambroxol Treatment. Respiration 1989; 55 suppl(1): 79-83.

  9. Baur X. Treatment of the Severe Asthma Attack and Status Asthmaticus. Fortschr Med 1989;107:91-95.

  10. Baldini G, Guccci M, Taro D, Memmini C. A Controlled Study on the Action of a New Formulation of Ambroxol in Asthmatiform Bronchitis in Children. Minerva Pediatr 1989;41:91-95.

  11. American Thoracic Society. Medical Section of the American Lung Association. ATS Standardization of Spirometry–1987 update. Am Rev Respir Dis 1987;136:1285-1298.

  12. Sturges JM. Mucous Secretions in the Respiratory Tract. Ped Clin North Am 1979;26:481-501.

  13. Ramzi SC, Vinay K, Tucker C. Robbins. Patología Estructural y Funcional. 6a ed. Madrid: McGraw-Hill, 2000:746.

  14. Adkinson F, Ynginger J, Busse W. Allergy Principles and Practice. 14th ed. St. Louis: Mosby, 1998:520-531.

  15. Johnston SL. Bronchial Hyperresponsivenes and Cytokines in Virus Induced Asthma Exacerbations. Clin Experimental Allergy 1997;27: 7-9.




2020     |     www.medigraphic.com